Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Green dye could replace radioactive tracers in breast cancer surgery

NCT ID NCT07146295

Knowledge-focused Sponsor: Isabelle Henskens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to help Dutch hospitals switch from using a radioactive tracer to a green dye called indocyanine green (ICG) to find the first lymph node that breast cancer may spread to. The dye is given during surgery, avoids radiation, and requires no extra hospital visits. Researchers will roll out the change step-by-step in several hospitals and gather feedback from patients and doctors to create a guide for nationwide use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Indocyanine green (ICG) dye
What this could lead to
If successful, this could make sentinel lymph node biopsy during breast cancer surgery safer, cheaper, and more convenient by replacing radioactive tracers with a dye given during surgery.
What could go wrong
This is an implementation study, not a test of effectiveness. ICG is already known to work as well as the standard method, so the main risk is that hospitals may not adopt it smoothly or that patient feedback reveals issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,760 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥ 18 years old. * DCIS or invasive breast cancer, confirmed by biopsy * Clinically node-negative, confirmed by preoperative axillary ultrasound * Indication for breast cancer surgery with SLN procedure via axillar incision Exclusion Criteria: * Combined MARI procedure * Known allergy for Indocyanine Green (ICG), intravenous contrast or iodine * History of axillary lymph node dissection * Hyperthyroidism or thyroid cancer * Pregnancy or breast-feeding * No written informed consent according to ICH/GCP and national regulations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Lymphatic Metastasis metastatic malignant neoplasm in the lymph nodes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Fluorescence imaging Indocyanine green (ICG) Lymph node mapping Lymphatic metastasis Radioisotopes Sentinel lymph node Sentinel lymph node biopsy (SLNB) Sentinel lymph node detection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    7 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alrijne Hospital

    RECRUITING

    Leiden, Netherlands

  • Canisius Wilhelmina Ziekenhuis

    RECRUITING

    Nijmegen, Netherlands

  • Diakonessenhuis

    RECRUITING

    Utrecht, Netherlands

    Contact Email: •••••@•••••

  • Dijklander Ziekenhuis

    RECRUITING

    Hoorn, Netherlands

  • Noordwest Ziekenhuisgroep

    RECRUITING

    Alkmaar, Netherlands

  • Spaarne Gasthuis

    RECRUITING

    Hoofddorp, Netherlands

  • Ziekenhuisgroep Twente

    RECRUITING

    Hengelo, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.